Supplemental material
Future Oncology
Volume 17, 2021 - Issue 1
Meta Analysis
Indirect Analysis of First-Line Therapy for Advanced Non-Small-Cell Lung Cancer with Activating Mutations in a Japanese Population
Kazuhiko Nakagawa1 Department of Medical Oncology, Kindai University, Faculty of Medicine,Osaka,JapanCorrespondence[email protected]
https://orcid.org/0000-0003-1284-9776View further author information
https://orcid.org/0000-0003-1284-9776View further author information, , Tayler Scory3 Medlior Health Outcomes Research Ltd. Calgary,ABT2C 5P9,Canadahttps://orcid.org/0000-0002-7663-8436View further author information
https://orcid.org/0000-0002-7663-8436View further author information, , Kelly A Larkin-Kaiser3 Medlior Health Outcomes Research Ltd. Calgary,ABT2C 5P9,Canadahttps://orcid.org/0000-0001-6205-0212View further author information
https://orcid.org/0000-0001-6205-0212View further author information, Hironori Kikkawa2 Pfizer Japan,Tokyo,Japanhttps://orcid.org/0000-0002-3663-4297View further author information
https://orcid.org/0000-0002-3663-4297View further author information, Jasmina I Ivanova4 Pfizer,New York,NY10017,USAhttps://orcid.org/0000-0002-4028-9676View further author information
https://orcid.org/0000-0002-4028-9676View further author information & Keith D Wilner5 Pfizer,La Jolla,CA92121,USAhttps://orcid.org/0000-0002-2276-7865View further author information
https://orcid.org/0000-0002-2276-7865View further author information show all